Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Biotech HepaHope on IPO

5/1/2009

WASHINGTON, DC, May 1, 2009 — Covington & Burling LLP advised California-based biotech HepaHope, Inc. on its initial public offering in Germany and Luxembourg and its listing on the Frankfurt Stock Exchange. HepaHope raised a total of $12.6 million from funding activities in connection with the IPO.

The offering had to be carefully structured and managed to ensure compliance with SEC Regulation S, which permits offers and sales of securities by US companies outside the United States without the need to file an SEC registration statement. The IPO is the first in Germany in more than nine months.

HepaHope, Inc. is a biopharmaceutical company focused on research, development and commercialization of biologic products designed to address the needs of patients with liver failure.

The Covington corporate team was led by Tod Ackerly.

Share this article: